NCT05035667
Patient Considerations of Social Media Account Management After Death No drug interventions Not Available Not Available active_not_recruiting NCT05038839
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors treatment 1 active_not_recruiting NCT05564377
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial screening 2 recruiting NCT05638295
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) treatment 2 recruiting NCT06357975
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) treatment 2 active_not_recruiting NCT06357988
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) treatment 2 active_not_recruiting NCT06360575
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) treatment 2 active_not_recruiting NCT06630325
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer treatment 2 not_yet_recruiting NCT06630351
Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients with Advanced Cancer No drug interventions supportive_care Not Available enrolling_by_invitation NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) screening 2 active_not_recruiting NCT03210714
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT03213678
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT03213704
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT04294628
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer treatment 1 active_not_recruiting NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV treatment 1 active_not_recruiting NCT04704661
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial treatment 1 recruiting NCT05969860
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients with Advanced Cancer No drug interventions health_services_research 2 recruiting NCT06311214
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) treatment 2 not_yet_recruiting NCT03155620
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) screening 2 recruiting NCT03213652
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) treatment 2 recruiting NCT03526250
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT03698994
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT04197713
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study treatment 1 active_not_recruiting NCT04511039
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer treatment 1 recruiting NCT05327010
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial treatment 2 recruiting NCT05687136
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors treatment 1 recruiting NCT05705492
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Solid or or Metastatic Esophagogastric, Hepatopancreaticobiliary, or Lung Cancer supportive_care 2 recruiting NCT04984551
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia No drug interventions supportive_care Not Available recruiting NCT04989556
Technology-Enhanced Palliative Care for Advanced Cancer Patients No drug interventions supportive_care Not Available active_not_recruiting NCT05053971
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas treatment 1 / 2 recruiting NCT05058339
Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer No drug interventions Not Available Not Available completed NCT06223542
Studying TAK-243 in Patients With Advanced Cancer treatment 1 recruiting NCT06303167
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) treatment 2 active_not_recruiting NCT06308822
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) treatment 2 active_not_recruiting NCT01827384
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations treatment 2 completed NCT04439279
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) treatment 2 active_not_recruiting NCT03253679
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification treatment 2 completed NCT04785287
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies treatment 1 / 2 active_not_recruiting NCT05967533
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors No drug interventions treatment 1 recruiting NCT00576654
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT03784677
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors treatment 1 completed NCT04317105
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN treatment 1 / 2 active_not_recruiting NCT06385483
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) treatment 2 active_not_recruiting NCT03842228
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations treatment 1 active_not_recruiting NCT05490771
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) treatment 2 active_not_recruiting NCT04439188
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) treatment 2 active_not_recruiting NCT04870788
Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers No drug interventions supportive_care Not Available recruiting NCT02503709
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT01591356
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors No drug interventions treatment 1 active_not_recruiting NCT03927885
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer No drug interventions supportive_care 2 / 3 active_not_recruiting NCT06390852
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) treatment 2 active_not_recruiting NCT02070549
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction treatment 1 active_not_recruiting NCT03725436
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors treatment 1 active_not_recruiting NCT02498613
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors treatment 2 active_not_recruiting NCT03830918
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy treatment 1 / 2 recruiting NCT05691517
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers treatment 1 recruiting NCT04616534
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors treatment 1 active_not_recruiting NCT01434316
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors treatment 1 active_not_recruiting NCT06385496
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) treatment 2 active_not_recruiting NCT03326258
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery treatment 1 / 2 withdrawn NCT02650986
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 treatment 1 / 2 active_not_recruiting NCT01738139
Ipilimumab and Imatinib Mesylate in Advanced Cancer treatment 1 completed NCT01822522
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus treatment 1 completed NCT06400225
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) treatment 2 active_not_recruiting NCT05791448
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease No drug interventions treatment 1 recruiting NCT06390826
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) treatment 2 active_not_recruiting NCT03213665
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT02317874
Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer treatment 1 completed NCT03872427
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study treatment 2 active_not_recruiting NCT05403580
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer supportive_care 3 withdrawn NCT04439292
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) treatment 2 active_not_recruiting NCT04902040
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies treatment 1 / 2 recruiting NCT01628640
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors treatment 1 active_not_recruiting NCT02227940
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer treatment 1 completed NCT04233567
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations treatment 2 active_not_recruiting NCT04439201
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) treatment 2 active_not_recruiting NCT05039801
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors treatment 1 recruiting NCT04693468
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial treatment 1 recruiting NCT02419495
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies treatment 1 active_not_recruiting NCT04439214
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) treatment 2 completed NCT03583255
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer supportive_care 2 / 3 active_not_recruiting NCT03291938
IACS-010759 in Advanced Cancers No drug interventions treatment 1 completed NCT04021043
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers treatment 1 / 2 active_not_recruiting NCT02152943
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients treatment 1 completed NCT03537690
FID-007 in Treating Participants With Advanced Solid Tumors treatment 1 recruiting NCT04939090
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients supportive_care 3 recruiting NCT03237390
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors treatment 1 completed NCT06400264
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) treatment 2 withdrawn NCT03065387
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation treatment 1 active_not_recruiting NCT03017833
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers treatment 1 completed NCT01480154
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer treatment 1 active_not_recruiting NCT06400251
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) treatment 2 active_not_recruiting NCT04439253
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) treatment 2 active_not_recruiting NCT02451553
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer treatment 1 completed NCT04871477
Adoption of Audio Recording in the Outpatient Supportive Care Center No drug interventions Not Available Not Available not_yet_recruiting NCT03217747
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies treatment 1 / 2 active_not_recruiting NCT06320405
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors treatment 1 / 2 recruiting NCT04439305
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) treatment 2 withdrawn NCT05653661
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors treatment 1 recruiting NCT02408861
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 recruiting NCT05111561
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer treatment 1 suspended NCT03925428
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas treatment 1 withdrawn NCT06470971
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial treatment 2 recruiting NCT03035409
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors supportive_care 2 active_not_recruiting NCT02389309
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors treatment 1 active_not_recruiting NCT05101356
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma treatment 1 / 2 recruiting NCT02721732
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic treatment 2 active_not_recruiting NCT05039632
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies No drug interventions treatment 1 / 2 recruiting NCT05733000
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors treatment 2 recruiting NCT04439175
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) treatment 2 active_not_recruiting NCT04491942
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer treatment 1 active_not_recruiting NCT05455606
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment No drug interventions health_services_research Not Available recruiting NCT04439149
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) treatment 2 active_not_recruiting NCT04439136
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) treatment 2 active_not_recruiting NCT04439318
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) treatment 2 active_not_recruiting NCT03756818
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT04090619
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers No drug interventions Not Available Not Available active_not_recruiting NCT04171219
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers treatment 2 active_not_recruiting NCT01303341
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma treatment 1 active_not_recruiting NCT04697524
Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer No drug interventions supportive_care Not Available completed NCT03220035
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT06390839
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) treatment 2 active_not_recruiting NCT04729725
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL treatment 1 terminated NCT04678648
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies No drug interventions treatment 1 recruiting NCT04439357
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) treatment 2 active_not_recruiting NCT03218826
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT04439266
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) treatment 2 active_not_recruiting NCT06390865
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) treatment 2 active_not_recruiting NCT03212274
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations treatment 2 active_not_recruiting NCT05238831
SMMART Adaptive Clinical Treatment (ACT) Trial treatment 0 withdrawn NCT04439331
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) treatment 2 active_not_recruiting NCT04439227
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) treatment 2 active_not_recruiting NCT03213691
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT05691491
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness treatment 1 / 2 recruiting NCT02159989
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 completed NCT04439344
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) treatment 2 active_not_recruiting NCT04439240
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) treatment 2 completed NCT04552704
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study treatment 1 / 2 terminated NCT03233204
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) treatment 2 completed NCT02535312
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin treatment 1 / 2 active_not_recruiting NCT04439110
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) treatment 2 active_not_recruiting NCT03831295
SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies treatment 1 completed NCT04439123
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) treatment 2 active_not_recruiting NCT06400238
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) treatment 2 active_not_recruiting NCT04908046
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors treatment 1 completed NCT06231550
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors No drug interventions treatment 1 active_not_recruiting NCT06499350
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors treatment 1 / 2 not_yet_recruiting NCT05773937
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors No drug interventions treatment 1 recruiting NCT05383703
Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor No drug interventions treatment 1 unknown_status NCT00884845
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors treatment 1 completed NCT01290471
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors No drug interventions treatment 1 completed NCT02690337
Study of DS-1123a in Advanced Solid Tumours No drug interventions treatment 1 completed NCT04328506
Bioequivalency Study of CM082 Tablet in Healthy Volunteers No drug interventions treatment 1 completed NCT00958724
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors treatment 1 completed NCT03792958
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors No drug interventions treatment 1 active_not_recruiting NCT06571422
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors treatment 1 not_yet_recruiting NCT00706030
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer treatment 1 / 2 completed NCT05338957
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. treatment 1 / 2 recruiting NCT01334073
Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors treatment 1 completed NCT05749627
Using Neoantigen Peptide Vaccine/Neoantigen-based DC to Treat Advanced Malignant Solid Tumors No drug interventions treatment Not Available recruiting NCT02675491
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors treatment 1 completed NCT00728468
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients Not Available 1 completed NCT00768469
Study Evaluating Safety And Tolerability, Solid Tumor treatment 1 completed NCT05277454
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT No drug interventions treatment 1 recruiting NCT03047811
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors No drug interventions treatment Not Available unknown_status NCT00503711
Phase I Chinese PK treatment 1 completed NCT05478785
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors treatment 1 / 2 not_yet_recruiting NCT05949775
Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors No drug interventions treatment Not Available not_yet_recruiting NCT01128842
A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor treatment 1 completed NCT00445458
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer treatment 1 / 2 completed NCT04226066
Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors No drug interventions treatment 1 / 2 unknown_status NCT05886374
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors No drug interventions treatment 1 recruiting NCT00997360
Study of PKI-179 Administered Orally to Subjects With Solid Tumors treatment 1 withdrawn NCT02192567
Open Label Study of DS-5573a No drug interventions treatment 1 terminated NCT04126668
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers No drug interventions treatment 1 completed NCT02045095
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors treatment 1 terminated NCT06464055
A Study of GQ1010 in Subjects With Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT04241835
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function treatment 1 recruiting NCT06150183
Safety and Preliminary Efficacy of BNT314 with or Without an Immune Checkpoint Inhibitor in Cancer Patients with Malignant Solid Tumors treatment 1 / 2 recruiting NCT06573294
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors No drug interventions treatment 1 recruiting NCT06592417
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors No drug interventions treatment 1 recruiting NCT04165590
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT05911984
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors No drug interventions treatment 1 not_yet_recruiting NCT03662815
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor No drug interventions treatment 1 unknown_status NCT05396339
A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. No drug interventions treatment 1 / 2 recruiting NCT03171220
Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors treatment 1 / 2 unknown_status NCT04275050
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets No drug interventions treatment 1 unknown_status NCT04864379
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors No drug interventions treatment 1 recruiting NCT05098405
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors No drug interventions treatment 1 terminated NCT04758897
Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors treatment 1 unknown_status NCT05477849
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors No drug interventions treatment 1 recruiting NCT02993913
Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid Tumor No drug interventions Not Available 1 unknown_status NCT06166472
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor No drug interventions treatment 1 not_yet_recruiting NCT05271292
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. treatment 1 / 2 recruiting NCT04606381
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies treatment 1 active_not_recruiting NCT05417594
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies treatment 1 / 2 recruiting NCT06028074
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies No drug interventions treatment 1 / 2 recruiting NCT04521413
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies treatment 1 / 2 recruiting NCT00986843
Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102) treatment 1 completed NCT00572364
Open Label, Dose Escalation Phase I Study of AZD2281 treatment 1 completed NCT00937664
Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine treatment 1 terminated NCT00981721
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies treatment 1 completed NCT04353102
A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies No drug interventions treatment 1 completed NCT01455584
Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors treatment 1 completed NCT02575651
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies treatment 1 completed NCT02398747
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies treatment 1 completed NCT00669097
Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies treatment 1 completed NCT01024283
Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor No drug interventions Not Available Not Available unknown_status NCT03363893
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies treatment 1 / 2 completed NCT03084471
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. treatment 3 completed NCT02740985
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies treatment 1 completed NCT00871559
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies No drug interventions treatment 1 completed NCT00979134
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours treatment 1 terminated NCT05573724
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies treatment 1 completed NCT00473616
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan treatment 1 terminated NCT00979563
Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies treatment 1 completed NCT00351325
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies treatment 1 terminated NCT00733031
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918 treatment 1 terminated NCT00973076
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 treatment 1 completed NCT01213160
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient treatment 1 completed NCT01103791
A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies treatment 1 completed NCT05315167
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT02350868
Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment No drug interventions treatment 1 completed NCT01351350
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies treatment 1 completed NCT01219543
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. treatment 1 terminated NCT03980821
A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies other 1 completed NCT01026402
Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 treatment 1 completed NCT06388902
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies No drug interventions treatment 1 not_yet_recruiting NCT00997945
10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies basic_science 1 completed NCT00879905
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors No drug interventions treatment 1 completed NCT02260661
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours treatment 1 completed NCT02347228
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies No drug interventions treatment 1 recruiting NCT02080078
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline treatment 1 terminated NCT01058707
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies treatment 1 completed NCT05159700
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT01102400
A Study of MEDI-575 in Patients With Advanced Solid Malignancies treatment 1 completed NCT05469919
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies treatment 1 completed NCT04136834
A Phase I Open-label Study for Subjects With Advanced Malignancies No drug interventions treatment 1 unknown_status NCT01605916
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer treatment 1 completed NCT00637039
Study of AZD8931 in Patients With Advanced Solid Malignancies treatment 1 completed NCT01800630
Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas other 1 completed NCT01588548
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma No drug interventions treatment 1 completed NCT01813474
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies treatment 1 completed NCT03736473
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients other 1 completed NCT03394144
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies treatment 1 completed NCT01340040
Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects treatment 1 completed NCT00295243
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies treatment 1 completed NCT01226316
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules treatment 1 active_not_recruiting NCT01895946
Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability treatment 1 completed NCT01353781
Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies treatment 1 completed